Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 2:29 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 20,936 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Non-treatment Clear all
Active, not recruiting No phase listed Observational

Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies

NCT01115777
View directory record Official record
Conditions
Brain Tumors, Non-CNS Malignancies
Interventions
Quality of Life surveys completed at specified timepoints
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
2 Years to 25 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 3 Interventional Results available

Pharmacogenetics of Nicotine Addiction Treatment

NCT01314001
View directory record Official record
Conditions
Nicotine Addiction
Interventions
Varenicline, Placebo, Transdermal Nicotine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
1,246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Buffalo, New York • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2016 · Synced Nov 6, 2026, 2:29 PM EST
Completed No phase listed Observational

Biomarker Establishment for Superior Treatment of PTSD

NCT03343028
View directory record Official record
Conditions
PTSD
Interventions
Psychotherapy
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 60 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Palo Alto, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2020 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 3 Interventional Results available

Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).

NCT03790137
View directory record Official record
Conditions
Photosensitive Epilepsy
Interventions
Fenfluramine Hydrochloride
Drug
Lead sponsor
Elizabeth Anne Thiele
Other
Eligibility
4 Years to 25 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Nov 6, 2026, 2:29 PM EST
Terminated Phase 1Phase 2 Interventional Results available

Phase II Study of TAK228 in Relapsed Lymphoma

NCT02727777
View directory record Official record
Conditions
Lymphoma
Interventions
TAK228, Blood Sugar Testing
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional Results available

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

NCT03876457
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
19
States / cities
Los Angeles, California • Jacksonville, Florida • Chicago, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 3 Interventional Results available

Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A

NCT01138501
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
turoctocog alfa
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Up to 11 Years · Male only
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
18
States / cities
Phoenix, Arizona • Orange, California • Torrance, California + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Nov 6, 2026, 2:29 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Health and Health Care Utilization Effects of Medical Debt Forgiveness

NCT04835012
View directory record Official record
Conditions
Health Care Utilization, Depression, Anxiety, Subjective Wellbeing
Interventions
Medical debt forgiveness
Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
15,008 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional Results available

A Safety and Effectiveness Study of JUVÉDERM VOLBELLA® XC Injectable Gel for Lip and Perioral Enhancement

NCT01998581
View directory record Official record
Conditions
Subjects Desiring Lip Augmentation
Interventions
JUVEDERM VOLBELLA® XC, Restylane-L®
Device
Lead sponsor
Allergan
Industry
Eligibility
22 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 26, 2019 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional Results available

Sleep, Hypertension, and Nocturia: a Multicomponent Approach for Comorbid Illnesses

NCT05419830
View directory record Official record
Conditions
Nocturia, Hypertension, Sleep Disturbance
Interventions
BBTI, PM antihypertensive dosing or Chronotherapy, AM antihypertensive dosing
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional

Continued Activity During Rehabilitation in Patients With Patellar Tendinopathy

NCT03694730
View directory record Official record
Conditions
Patellar Tendinopathy, Patellar Tendinitis, Patellar Tendon Pain, Patellar Tendinosis, Jumper's Knee
Interventions
Exercise Treatment, Pain- Guided Activity Modification
Other
Lead sponsor
University of Delaware
Other
Eligibility
16 Years to 40 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional Results available

Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax

NCT02322528
View directory record Official record
Conditions
Sjogren's Disease
Interventions
Administration of Lotemax
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 16, 2015 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional

Advance Care Planning in Cognitive Disorders Clinic

NCT03864965
View directory record Official record
Conditions
Advance Care Planning
Interventions
Advance Care Planning
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

A Study To Monitor Long-Term Treatment With PF-00547659

NCT01298492
View directory record Official record
Conditions
Crohn's Disease
Interventions
PF-00547659
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
47
States / cities
La Jolla, California • Orange, California • Lafayette, Colorado + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2021 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 2 Interventional Results available

Janus Kinase Inhibition in Granuloma Annulare

NCT05650736
View directory record Official record
Conditions
Granuloma Annulare
Interventions
Abrocitinib 200 mg
Drug
Lead sponsor
William Damsky
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 2 Interventional

Fentanyl Transdermal Matrix Patch ZR-02-01 to Treat Chronic, Moderate to Severe Osteoarthritis (OA) Pain

NCT00108771
View directory record Official record
Conditions
Pain
Interventions
ZR-02-01 Fentanyl Transdermal Matrix Patch, Placebo Patch
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
40 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
13
States / cities
Phoenix, Arizona • San Diego, California • Upland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2012 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Non-Specific Effects of Manual Therapy

NCT03017534
View directory record Official record
Conditions
Musculoskeletal Manipulations, Placebo Effect
Interventions
Spinal Manual Therapy
Procedure
Lead sponsor
Shenandoah University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Winchester, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 9, 2017 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 2 Interventional

TC-5214 as add-on the Treatment of Major Depressive Disorder

NCT00692445
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
TC-5214 + citalopram, Placebo + citalopram
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
3
States / cities
Miami, Florida • Cincinnati, Ohio • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 21, 2013 · Synced Nov 6, 2026, 2:29 PM EST
Recruiting Phase 2 Interventional

Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy

NCT06411795
View directory record Official record
Conditions
Duodenal Neoplasm, Pancreatic Neoplasm
Interventions
Bupivacaine, Hydromorphone, Iopamidol, Liposomal Bupivacaine, Medical Chart Review, Questionnaire Administration, Thoracic Epidural Analgesia, Ultrasound Imaging, X-Ray Imaging
Drug · Other · Procedure
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 1 Interventional

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

NCT00004095
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer
Interventions
gemcitabine hydrochloride, irinotecan hydrochloride
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 120 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Nov 6, 2026, 2:29 PM EST
Terminated Phase 1Phase 2 Interventional

Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides

NCT00052377
View directory record Official record
Conditions
Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome
Interventions
aldesleukin, recombinant interleukin-12, laboratory biomarker analysis
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 2 Interventional

Thalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00022581
View directory record Official record
Conditions
Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
thalidomide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 7, 2013 · Synced Nov 6, 2026, 2:29 PM EST
Completed Phase 3 Interventional

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

NCT00370565
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Inhaled Human Insulin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
35 Years to 80 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
37
States / cities
Irvine, California • Long Beach, California • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2007 · Synced Nov 6, 2026, 2:29 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Comparing a Novel Phototherapy Kiosk to Oral Vitamin D Supplementation

NCT04556136
View directory record Official record
Conditions
Hypovitaminosis D
Interventions
Standing Phototherapy Kiosk, D3 Oral supplement
Device · Dietary Supplement
Lead sponsor
Madigan Army Medical Center
Federal
Eligibility
18 Years to 69 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Mar 13, 2024 · Synced Nov 6, 2026, 2:29 PM EST